Inspirna, Inc.

Back in March when it unveiled its full-year 2023, Merck KGaA made it clear that it was on the lookout for licensing deals. (Also see " Merck KGaA Wants Your Drugs " - Scrip, 7 March, 2024.) Today,

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Coherus Ends TIGIT Pact With Junshi Des

Knopp Biosciences LLC and the private equity firm Population Health Partners launched Areteia Therapeutics Inc. on July 12 with up to $350m to take Knopp’s dexpramipexole into Phase III clinical tr